Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABACUS phase II preoperative atezolizumab in operable bladder cancer
NL-OMON47135Phase 2Active, not recruiting
- Sponsor
- Queen Mary University of London
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by Queen Mary University of London. Primary endpoints: Pathological complete response rate and Dynamic changes in T-cell subpopulations. Started Mar 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NL-OMON47135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47135.